Biomarker Kinetics ™ : CA-125 KELIM ™ Calculator in Ovarian Cancer & Other Biomarkers

Changes in serum tumor biomarkers may indicate treatment efficacy. Mathematical modeling allows calculation of the equations describing the longitudinal tumor biomarker time-changes. The model-based population kinetic approach is particularly relevant as it enables determination of individual kinetic profiles parameters based on a few timepoints, with limited impact of inter- and intra-individual variability of timepoints and assays.

Our tools

The team

The models were developed by Team 3 of EA3738 CICLY of Lyon University (Université Claude Bernard Lyon 1, France) and Lyon University Hospital (Hospices Civils de Lyon, France), in collaboration with the collaborative French GINECO Group, under the supervision of Prof Benoit You MD PhD. The internet site and the smartphone application were developed with the support of HCL Fondation.

More about the team >
Université Claude Bernard Lyon 1 HCL Fondation HCL

BK™ Smartphone App™ also works on your smartphone!

To add it to your home screen:

  1. 1
    Open Safari or Chrome
  2. 2
    tap the icon in Safari, or
    tap the icon in Chrome
  3. 3
    Select "Add to Home Screen"

Interested in collaboration for your datasets or your innovative drugs ? So are we!

Learn more >


Who does use KELIM in the world ?

Who does use KELIM in the world ?

Almost everyone ! The CA-125 KELIM is calculated > 2000 times every month in the world in > 50% of countries on the globe ! 50% on the neo-adjuvant engine et 50% on the adjuvant engine ...

ESGO 2024: Oral presentation

ESGO 2024: Oral presentation

Oral presentation at ESGO 2024: Benefit From Atezolizumab In Patients With A Poor Prognostic Ovarian Cancer In First-Line Setting: IMAGYN 050 Trial Benoit You et al. Session Date: 8 March 2024Session Time: 10:55-11:55

More >
Salvovar logo

Learn more about the future European clinical phase III trial SALVOVAR, where the patients with unfavorable KELIM score < 1.0 and a disease not amenable to complete interval debulking surgery after 3 to 4 cycles standard neo-adjuvant chemotherapy will be randomized to the continuation of the standard 3-weekly regimen, or a salvage regimen with weekly dose-dense carboplatin-paclitaxel

Visit website >